Efinopegdutide
Hanmi\'s GLP-1/Glucagon Dual Agonist
Efinopegdutide is a long-acting dual GLP-1 and glucagon receptor agonist developed by Hanmi Pharmaceutical and partnered with MSD (Merck). Its dual mechanism targets both appetite regulation (via GLP-1) and energy expenditure (via glucagon). It has shown particular promise for reducing liver fat, positioning it as a potential treatment for MASH (metabolic dysfunction-associated steatohepatitis). Use the Shotlee app to track your current protocol and build baseline data for whatever comes next.
What Is Efinopegdutide?
Efinopegdutide is a long-acting dual GLP-1 and glucagon receptor agonist developed by Hanmi Pharmaceutical and partnered with MSD (Merck). Its dual mechanism targets both appetite regulation (via GLP-1) and energy expenditure (via glucagon). It has shown particular promise for reducing liver fat, positioning it as a potential treatment for MASH (metabolic dysfunction-associated steatohepatitis).
Track your current protocol in Shotlee while this science evolves. Having clean historical data means you can compare outcomes with precision if you ever switch medications.
How It Works
GLP-1 Agonism
- • Appetite suppression
- • Improved insulin sensitivity
- • Blood sugar regulation
- • Track metabolic data in Shotlee
Glucagon Agonism
- • Increases energy expenditure
- • Promotes liver fat breakdown
- • Boosts calorie burning
- • Monitor body comp in Shotlee
Liver Focus
- • Significant liver fat reduction
- • MASH treatment potential
- • Dual metabolic attack
- • Log all results in Shotlee
Why This Matters
By adding glucagon receptor activation to GLP-1 signaling, efinopegdutide increases energy expenditure while reducing appetite — attacking obesity from both sides. The liver fat reduction makes it especially relevant for MASH patients.
Clinical Data
Phase 2 showed approximately 9% weight loss with significant liver fat reduction in MASH patients.
Demonstrated substantial reduction in liver fat content, potentially treating MASH.
Side Effects
- • Nausea (GI class)
- • Decreased appetite
- • Dose-dependent effects
- • Log symptoms in Shotlee
Vital Protocol FAQs
What is Efinopegdutide?
It is a dual GLP-1 and glucagon receptor agonist developed by Hanmi/MSD, notable for its liver fat reduction capabilities. Track your protocol in Shotlee.
Is it only for liver disease?
No, it is being studied for both obesity and MASH. The dual mechanism benefits weight loss and liver health simultaneously. Use Shotlee to monitor your progress.
Prepare for Better Protocol Outcomes
Track your protocol with Shotlee and make every decision from clean, visible data instead of guesswork.
🚀 Use Shotlee for Free